Enhancing the QUAlity and Transparency Of health Research
Use your browser's Back button to return to your search results
|Reporting guideline provided for?
(i.e. exactly what the authors state in the paper)
|Reporting of post-introduction COVID-19 vaccine effectiveness evaluations.|
|Full bibliographic reference||Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, Hirve S, Kang G, Katz MA, Lanata CF, L'Azou Jackson M, Joshi S, Lipsitch M, Mwenda JM, Nogareda F, Orenstein WA, Ortiz JR, Pebody R, Schrag SJ, Smith PG, Srikantiah P, Subissi L, Valenciano M, Vaughn DW, Verani JR, Wilder-Smith A, Feikin DR. Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. Vaccine. 2021:S0264-410X(21)00707-6.|
(full-text if available)
|The full-text of this guideline is freely available.
Table 4 presents an extension to the Strengthening the reporting of observational studies in epidemiology (STROBE) checklist with recommended additional elements for reporting COVID-19 vaccine effectiveness studies.
|Study design||Observational studies|
|Clinical area||Infectious diseases, Public health|
|Applies to the whole report or to individual sections of the report?||Whole report|
|Other||Linkins LA, Iorio A, Little J, Lavis J. Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19. Vaccine. 2022:S0264-410X(22)00422-4. PMID: 35443916|
|Record last updated on||April 29, 2022|
Some reporting guidelines are also available in languages other than English. Find out more in our Translations section.